Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-01-22
2010-12-21
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S119000
Reexamination Certificate
active
07855204
ABSTRACT:
This invention relates to novel quinazoline derivatives, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by inhibiting cell surface tyrosine receptor kinases.
REFERENCES:
patent: 4070289 (1978-01-01), Akcasu
patent: 6221335 (2001-04-01), Foster
patent: 6258951 (2001-07-01), Lohmann et al.
patent: 6440710 (2002-08-01), Keinan et al.
patent: 6603008 (2003-08-01), Ando et al.
patent: 7517990 (2009-04-01), Ito et al.
patent: 7598273 (2009-10-01), Gant et al.
patent: 2004/0152759 (2004-08-01), Abrams et al.
patent: 2004/0158065 (2004-08-01), Barth et al.
patent: 2007/0082929 (2007-04-01), Gant et al.
patent: 2007/0197695 (2007-08-01), Potyen et al.
patent: 2007/0219203 (2007-09-01), Bakthavatchalam et al.
patent: 2008/0103122 (2008-05-01), Veltri
patent: WO-95/26325 (1995-10-01), None
patent: WO-2007/118651 (2007-10-01), None
Bai et al. Journal of Liquid Chromatography & Related Technologies; 2004, 27, 2743-2758.
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, pp. 205-213.
McKillop et al. Xenobiotica 2004, 34, 917-934.
McKillop et al. Xenobiotica 2004, 34, 983-1000.
McKillop et al. Xenobiotica 2005, 35, 39-50.
Kushner et al. Canadian Journal of Physiology and Pharmacology 1999, 77, 79-88.
Fisher et al. Current Opinion in Drug Discovert & Development 2009, 9, 101-109.
Shah et al. J. Oncol. Pharm. Practice 2003, 9, 151-160.
Luo et al. Cell 2009, 136, 823-837.
International Search Report and Written Opinion dated Mar. 18, 2009, in corresponding PCT Patent Application No. PCT/US09/00482.
Foster, A.B., Advances in Drug Research, vol. 14, pp. 1-40 (1985).
Prescribing Information for IRESSA (gefitinib), accessed at http://www.accessdata.fda.gov/drugsatfda—docs/label/2005/021399s008lbl.pdf, 2004.
Foster, A.B., “Deuterium isotope effects in studies of drug metabolism”, TIPS 524-527 (Dec. 1984).
Gouyette, A., Biomedical and Environmental Mass Spectrometry, vol. 15, 243-247 (1988).
Cherrah, Y. et al., Biomedical and Environmental Mass Spectrometry, vol. 14, Issue 11, pp. 653-657 (1987).
Dyck, L.E. et al., Journal of Neurochemistry, vol. 46, Issue 2, pp. 399-404 (1986).
Tonn, G.R., et al., Biological Mass Spectrometry, vol. 22, Issue 11, pp. 633-642 (1993).
Haskins, N.J., Biomedical Spectrometry, vol. 9, Issue 7, pp. 269-277 (1982).
Wolen, R.L., J. Clin. Pharmacology 26: 419-424 (1986).
Pieniaszek, H.J. et al., J. Clin. Pharmacol. 39:817-825 (1999).
Honma, S. et al., Drug Metab Dispos 15(4): 551-559 (1987).
Browne, T.R., Journal of Clinical Pharmacology 38: 213-220 (1998).
Baillie, T.A., Pharmacology Rev. 33:81-132 (1981).
Foster, A.B., Adv Drug Res, 14:1-40 (1985).
Anderson Rebecca L
Concert Pharmaceuticals Inc.
Coughlin Matthew P
Edwards Angell Palmer & & Dodge LLP
Hsi Jeffrey D.
LandOfFree
Derivatives of gefitinib does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of gefitinib, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of gefitinib will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4197486